Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Centessa Pharmaceuticals PLC ADR
260Current price
16.1 EUR
+0.2 EUR (+1.26%)
Last closed
17.5 USD
Company
www.centessa.com
ISIN
US1523091007
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
2 121 388 544 USD
Yield for 12 month
+129.23 %
1Y
3Y
5Y
10Y
15Y
260
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
26.14 USDP/E ratio
–Dividend Yield
–Current Year
+6 879 562 USD
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
+6 066 423 USD
Last Year
-130 919 USD
Current Quarter
-236 264 USD
Last Quarter
-236 264 USD
Key Figures 260
1 year
3 years
5 years
10 years
EBITDA
-155 099 008 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-24.54 %
PEG Ratio
–
Return On Equity TTM
-55.84 %
Wall Street Target Price
26.14 USD
Revenue TTM
6 853 000 USD
Book Value
2.54 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.55 USD
Diluted Eps TTM
-1.55 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 260
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 260
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 260
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
279.0305
Price Sales TTM
309.5562
Enterprise Value EBITDA
1.1183
Price Book MRQ
7.3925
Financials 260
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 260
For 52 weeks
5.58 USD
17.59 USD
50 Day MA
15.61 USD
Shares Short Prior Month
1 956 095
200 Day MA
11.45 USD
Short Ratio
3.66
Shares Short
2 012 240
Short Percent
1.93 %
BeatStart